X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES PANACEA BIOTECH ALKEM LABORATORIES/
PANACEA BIOTECH
 
P/E (TTM) x - 169.7 - View Chart
P/BV x 7.4 3.8 196.0% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ALKEM LABORATORIES   PANACEA BIOTECH
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
PANACEA BIOTECH
Mar-14
ALKEM LABORATORIES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,589149 1,068.6%   
Low Rs1,23282 1,497.0%   
Sales per share (Unadj.) Rs417.584.1 496.1%  
Earnings per share (Unadj.) Rs56.3-18.3 -307.5%  
Cash flow per share (Unadj.) Rs64.7-6.7 -966.0%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.983.7 349.9%  
Shares outstanding (eoy) m119.5761.25 195.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.4 246.1%   
Avg P/E ratio x25.1-6.3 -397.1%  
P/CF ratio (eoy) x21.8-17.2 -126.4%  
Price / Book Value ratio x4.81.4 349.0%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6537,074 2,384.0%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m9,1711,449 632.9%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m49,9155,154 968.5%  
Other income Rs m1,645100 1,648.4%   
Total revenues Rs m51,5615,254 981.5%   
Gross profit Rs m8,482-766 -1,106.9%  
Depreciation Rs m1,006711 141.5%   
Interest Rs m6711,503 44.6%   
Profit before tax Rs m8,451-2,881 -293.4%   
Minority Interest Rs m-11411 -1,053.7%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m1,60617 9,559.5%   
Profit after tax Rs m6,731-1,121 -600.3%  
Gross profit margin %17.0-14.9 -114.3%  
Effective tax rate %19.0-0.6 -3,258.3%   
Net profit margin %13.5-21.8 -62.0%  
BALANCE SHEET DATA
Current assets Rs m27,0623,810 710.2%   
Current liabilities Rs m15,3248,365 183.2%   
Net working cap to sales %23.5-88.4 -26.6%  
Current ratio x1.80.5 387.7%  
Inventory Days Days67156 42.7%  
Debtors Days Days4167 61.4%  
Net fixed assets Rs m12,61014,480 87.1%   
Share capital Rs m23961 390.0%   
"Free" reserves Rs m34,490903 3,819.0%   
Net worth Rs m35,0275,127 683.2%   
Long term debt Rs m1,2125,832 20.8%   
Total assets Rs m54,38719,433 279.9%  
Interest coverage x13.6-0.9 -1,484.1%   
Debt to equity ratio x01.1 3.0%  
Sales to assets ratio x0.90.3 346.1%   
Return on assets %13.62.0 692.9%  
Return on equity %19.2-21.9 -87.9%  
Return on capital %24.93.6 683.6%  
Exports to sales %12.924.5 52.8%   
Imports to sales %3.110.2 30.3%   
Exports (fob) Rs m6,4611,264 511.2%   
Imports (cif) Rs m1,540525 293.5%   
Fx inflow Rs m6,5631,539 426.4%   
Fx outflow Rs m3,012942 319.7%   
Net fx Rs m3,552597 594.7%   
CASH FLOW
From Operations Rs m7,259599 1,211.4%  
From Investments Rs m1,864-438 -425.7%  
From Financial Activity Rs m-9,273-303 3,064.3%  
Net Cashflow Rs m-150-141 106.2%  

Share Holding

Indian Promoters % 66.9 74.5 89.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 0.6 5,516.7%  
FIIs % 0.0 1.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 23.6 -  
Shareholders   68,381 10,259 666.5%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  PFIZER  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 20, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS